Integration of Energy Metabolism and Control of Apoptosis in Tumor Cells

  • John G. Pastorino
  • Jan B. Hoek


Poorly differentiated and rapidly growing tumor cells tend to have higher glycolytic rates than noncancerous cells and these high rates of glycolysis occur even under conditions where O2 is plentiful, resulting in high rates of lactate formation (Weinhouse1972; Pedersen2002; Gatenby and Gillies2004; Moreno-Sanchez2007; Kim and Dang2006). These observations indicate that the feedback control mechanisms that normally regulate the balance between glycolysis and mitochondrial oxidation under aerobic conditions are less effective in tumor cells. Although this unusual feature of energy metabolism in tumor cells (commonly referred to as the ‘Warburg effect’) was first described more than 80 years ago (Warburg1930), the recent resurgence of interest in the integration of metabolism with apoptosis and growth control has brought a renewed focus on the underlying mechanisms. Recent studies have provided evidence of a plethora of unexpected changes in energy metabolism that are...


Pyruvate Kinase Tuberous Sclerosis Complex Glycolytic Enzyme Glycolytic Flux Mitochondrial Oxidative Phosphorylation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Assaily, W. and Benchimol, S. 2006.Differential utilization of two ATP-generating pathways is regulated by p53. Cancer Cell, 10(1): 4–6.CrossRefPubMedGoogle Scholar
  2. Bernardi, R., et al. 2006.PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature, 442(7104): 779–85.CrossRefPubMedGoogle Scholar
  3. Bhaskar, P.T. and Hay, N. 2007.The two TORCs and Akt. Dev Cell, 12(4): 487–502.CrossRefPubMedGoogle Scholar
  4. Bijur, G.N. and Jope, R.S. 2003.Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria. Neuroreport, 14(18): 2415–9.CrossRefPubMedGoogle Scholar
  5. Bonnet, S., et al. 2007.A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell, 11(1): 37–51.CrossRefPubMedGoogle Scholar
  6. Boren, J., et al. 2001.Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem, 276(41): 37747–53.PubMedGoogle Scholar
  7. Brdiczka, D., et al. 1998.The molecular structure of mitochondrial contact sites. Their role in regulation of energy metabolism and permeability transition. Biofactors, 8(3–4): 235–42.CrossRefPubMedGoogle Scholar
  8. Burgering, B.M. and Kops, G.J. 2002.Cell cycle and death control: long live Forkheads. Trends Biochem Sci, 27(7): 352–60.CrossRefPubMedGoogle Scholar
  9. Buzzai, M., et al. 2007.Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res, 67(14): 6745–52.CrossRefPubMedGoogle Scholar
  10. Calissano, P., et al. 1985.Synthesis and content of a DNA-binding protein with lactic dehydrogenase activity are reduced by nerve growth factor in the neoplastic cell line PC12. Exp Cell Res, 161(1): 117–29.CrossRefPubMedGoogle Scholar
  11. Cantley, L.C. and Neel, B.G. 1999.New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA, 96(8): 4240–5.CrossRefPubMedGoogle Scholar
  12. Carling, D., 2004.The AMP-activated protein kinase cascade—A unifying system for energy control. Trends Biochem Sci, 29(1): 18–24.CrossRefPubMedGoogle Scholar
  13. Casey, J.R., 2006.Why bicarbonate? Biochem Cell Biol, 84(6): 930–9.CrossRefPubMedGoogle Scholar
  14. Cattaneo, A., et al. 1985.Nuclear localization of a lactic dehydrogenase with single-stranded DNA-binding properties. Exp Cell Res, 161(1): 130–40.CrossRefPubMedGoogle Scholar
  15. Chesney, J., 2006.6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis. Curr Opin Clin Nutr Metab Care, 9(5): 535–9.CrossRefPubMedGoogle Scholar
  16. Choo, A.Y. and Blenis, J. 2006.TORgeting oncogene addiction for cancer therapy. Cancer Cell, 9(2): 77–9.CrossRefPubMedGoogle Scholar
  17. Discher, D.J., et al. 1998.Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J Biol Chem, 273(40): 26087–93.CrossRefPubMedGoogle Scholar
  18. Dombrauckas, J.D., Santarsiero, and B.D. Mesecar, A.D. 2005.Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry, 44(27): 9417–29.CrossRefPubMedGoogle Scholar
  19. Edinger, A.L. and Thompson, C.B. 2002.Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell, 13(7): 2276–88.CrossRefPubMedGoogle Scholar
  20. Fang, J., et al. 2006.The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol Pharmacol, 70(6): 2108–15.CrossRefPubMedGoogle Scholar
  21. Fantin, V.R., St-Pierre, and J. Leder, P. 2006.Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 9(6): 425–34.CrossRefPubMedGoogle Scholar
  22. Fell, D., 1997:Understanding the Control of Metabolism. Portland Press, London.Google Scholar
  23. Fell, D.A., 1998.Increasing the flux in metabolic pathways: A metabolic control analysis perspective. Biotechnol Bioeng, 58(2–3): 121–4.CrossRefPubMedGoogle Scholar
  24. Fischer, K., et al. 2007.Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood, 109(9): 3812–9.CrossRefPubMedGoogle Scholar
  25. Forde, J.E. and Dale, T.C. 2007.Glycogen synthase kinase 3: A key regulator of cellular fate. Cell Mol Life Sci, 64(15): 1930–44.CrossRefPubMedGoogle Scholar
  26. Frey, T.G. and Mannella, C.A. 2000.The internal structure of mitochondria. Trends Biochem Sci, 25(7): 319–24.CrossRefPubMedGoogle Scholar
  27. Gatenby, R.A. and Gillies, R.J. 2004.Why do cancers have high aerobic glycolysis? Nat Rev Cancer, 4(11): 891–9.CrossRefPubMedGoogle Scholar
  28. Granville, D.J. and Gottlieb, R.A. 2003.The mitochondrial voltage-dependent anion channel (VDAC) as a therapeutic target for initiating cell death. Curr Med Chem, 10(16): 1527–33.CrossRefPubMedGoogle Scholar
  29. Hardie, D.G., 2004.The AMP-activated protein kinase pathway—New players upstream and downstream. J Cell Sci, 117(Pt 23): 5479–87.CrossRefPubMedGoogle Scholar
  30. Hardie, D.G., 2005.New roles for the LKB1→AMPK pathway. Curr Opin Cell Biol, 17(2): 167–73.CrossRefPubMedGoogle Scholar
  31. Hardt, P.D., et al. 2004.Faecal tumour M2 pyruvate kinase: A new, sensitive screening tool for colorectal cancer. Br J Cancer, 91(5): 980–4.PubMedGoogle Scholar
  32. Hay, N., 2005.The Akt-mTOR tango and its relevance to cancer. Cancer Cell, 8(3): 179–83.CrossRefPubMedGoogle Scholar
  33. Imai, K., et al. 2006.LKB1, an upstream AMPK kinase, regulates glucose and lipid metabolism in cultured liver and muscle cells. Biochem Biophys Res Commun, 351(3): 595–601.CrossRefPubMedGoogle Scholar
  34. Inoki, K., et al. 2002.TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol, 4(9): 648–57.CrossRefPubMedGoogle Scholar
  35. Inoki, K., Zhu, and T. Guan, K.L. 2003.TSC2 mediates cellular energy response to control cell growth and survival. Cell, 115(5): 577–90.CrossRefPubMedGoogle Scholar
  36. Inoki, K., et al. 2006.TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell, 126(5): 955–68.CrossRefPubMedGoogle Scholar
  37. Jones, R.G., et al. 2005.AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell, 18(3): 283–93.CrossRefPubMedGoogle Scholar
  38. Kacser, H. and Burns, J.A. 1973.The control of flux. Symp Soc Exp Biol, 27: 65–104.PubMedGoogle Scholar
  39. Kato, K., et al. 2002.Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene, 21(39): 6082–90.CrossRefPubMedGoogle Scholar
  40. Kim, A.H., et al. 2001.Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol, 21(3): 893–901.CrossRefPubMedGoogle Scholar
  41. Kim, J.W. and Dang, C.V. 2005.Multifaceted roles of glycolytic enzymes. Trends Biochem Sci, 30(3): 142–50.CrossRefPubMedGoogle Scholar
  42. Kim, J.W. and Dang, C.V. 2006.Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res, 66(18): 8927–30.CrossRefPubMedGoogle Scholar
  43. Kim, J.W., et al. 2006.HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab, 3(3): 177–85.CrossRefPubMedGoogle Scholar
  44. King, A., Selak, and M.A. Gottlieb, E. 2006.Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene, 25(34): 4675–82.CrossRefPubMedGoogle Scholar
  45. Kruse, J.P. and Gu, W. 2006.p53 aerobics: The major tumor suppressor fuels your workout. Cell Metab, 4(1): 1–3.CrossRefPubMedGoogle Scholar
  46. Kumar, Y., et al. 2007.Tumour M2-pyruvate kinase: A gastrointestinal cancer marker. Eur J Gastroenterol Hepatol, 19(3): 265–76.CrossRefPubMedGoogle Scholar
  47. Li, Y., et al. 2004.TSC2: Filling the GAP in the mTOR signaling pathway. Trends Biochem Sci, 29(1): 32–8.CrossRefPubMedGoogle Scholar
  48. Luo, Z., et al. 2005.AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci, 26(2): 69–76.CrossRefPubMedGoogle Scholar
  49. Ma, W., et al.,A pivotal role for p53: Balancing aerobic respiration and glycolysis. J Bioenerg Biomembr, 2007.Google Scholar
  50. MacKenzie, E.D., et al. 2007.Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol, 27(9): 3282–9.CrossRefPubMedGoogle Scholar
  51. Majewski, N., et al. 2004.Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell, 16(5): 819–30.CrossRefPubMedGoogle Scholar
  52. Manning, B.D. and Cantley, L.C. 2007.AKT/PKB signaling: Navigating downstream. Cell, 129(7): 1261–74.CrossRefPubMedGoogle Scholar
  53. Marchetti, P., et al. 1996.Mitochondrial permeability transition is a central coordinating event of apoptosis. Journal of Experimental Medicine, 184(3): 1155–60.CrossRefPubMedGoogle Scholar
  54. Marshall, S., 2006.Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: A nutritional perspective of diabetes, obesity, and cancer. Sci STKE, 2006(346): re7.CrossRefPubMedGoogle Scholar
  55. Mathupala, S.P., Heese, and C. Pedersen, P.L. 1997.Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem, 272(36): 22776–80.CrossRefPubMedGoogle Scholar
  56. Mathupala, S.P., Ko, and Y.H. Pedersen, P.L. 2006.Hexokinase II: Cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene, 25(34): 4777–86.CrossRefPubMedGoogle Scholar
  57. Matoba, S., et al. 2006.p53 regulates mitochondrial respiration. Science, 312(5780): 1650–3.CrossRefPubMedGoogle Scholar
  58. Mazurek, S., Boschek, and C.B. Eigenbrodt, E. 1997.The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J Bioenerg Biomembr, 29(4): 315–30.CrossRefPubMedGoogle Scholar
  59. Mazurek, S., et al. 2002.Pyruvate kinase type M2: A crossroad in the tumor metabolome. Br J Nutr, 87(Suppl 1): S23–9.CrossRefPubMedGoogle Scholar
  60. Mazurek, S., et al. 2005.Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol, 15(4): 300–8.CrossRefPubMedGoogle Scholar
  61. Minchenko, A., et al. 2002.Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem, 277(8): 6183–7.CrossRefPubMedGoogle Scholar
  62. Modur, V., et al. 2002.FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem, 277(49): 47928–37.CrossRefPubMedGoogle Scholar
  63. Moll, U.M., Marchenko, and N. Zhang, X.K. 2006.p53 and Nur77/TR3—Transcription factors that directly target mitochondria for cell death induction. Oncogene, 25(34): 4725–43.CrossRefPubMedGoogle Scholar
  64. Moreno-Sanchez, R., et al. 2007.Energy metabolism in tumor cells. Febs J, 274(6): 1393–418.CrossRefPubMedGoogle Scholar
  65. Papandreou, I., et al. 2006.HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab, 3(3): 187–97.CrossRefPubMedGoogle Scholar
  66. Pastorino, J.G. and Hoek, J.B. 2003.Hexokinase II: The integration of energy metabolism and control of apoptosis. Curr Med Chem, 10(16): 1535–51.CrossRefPubMedGoogle Scholar
  67. Pastorino, J.G., Shulga, and N. Hoek, J.B. 2002.Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem, 277(9): 7610–8.CrossRefPubMedGoogle Scholar
  68. Pastorino, J.G., Hoek, and J.B. Shulga, N. 2005.Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res, 65(22): 10545–54.CrossRefPubMedGoogle Scholar
  69. Pedersen, P.L., et al. 2002.Mitochondrial bound type II hexokinase: A key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta, 1555(1–3): 14–20.PubMedGoogle Scholar
  70. Pelicano, H., et al. 2006.Glycolysis inhibition for anticancer treatment. Oncogene, 25(34): 4633–46.CrossRefPubMedGoogle Scholar
  71. Plas, D.R. and Thompson, C.B. 2005.Akt-dependent transformation: There is more to growth than just surviving. Oncogene, 24(50): 7435–42.CrossRefPubMedGoogle Scholar
  72. Provent, P., et al. 2007.Serial in vivo spectroscopic nuclear magnetic resonance imaging of lactate and extracellular pH in rat gliomas shows redistribution of protons away from sites of glycolysis. Cancer Res, 67(16): 7638–45.CrossRefPubMedGoogle Scholar
  73. Reiling, J.H. and Hafen, E. 2004.The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev, 18(23): 2879–92.CrossRefPubMedGoogle Scholar
  74. Roe, J.S., et al. 2006.p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell, 22(3): 395–405.CrossRefPubMedGoogle Scholar
  75. Rutter, G.A., Da Silva Xavier, and G. Leclerc, I. 2003.Roles of 5′-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem J, 375(Pt 1): 1–16.CrossRefPubMedGoogle Scholar
  76. Schwarzer, R., et al. 2005.REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene, 24(7): 1138–49.CrossRefPubMedGoogle Scholar
  77. Semenza, G.L.,HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr, 2007.Google Scholar
  78. Shaw, R.J., 2006.Glucose metabolism and cancer. Curr Opin Cell Biol, 18(6): 598–608.CrossRefPubMedGoogle Scholar
  79. Shim, H., et al. 1997.c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth. Proc Natl Acad Sci USA, 94(13): 6658–63.CrossRefPubMedGoogle Scholar
  80. Shimizu, S., Narita, and M. Tsujimoto, Y. 1999.Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature, 399(6735): 483–7.CrossRefPubMedGoogle Scholar
  81. Stetak, A., et al. 2007.Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res, 67(4): 1602–8.CrossRefPubMedGoogle Scholar
  82. Sui, D. and Wilson, J.E. 1997.Structural determinants for the intracellular localization of the isozymes of mammalian hexokinase: Intracellular localization of fusion constructs incorporating structural elements from the hexokinase isozymes and the green fluorescent protein. Arch Biochem Biophys, 345(1): 111–25.CrossRefPubMedGoogle Scholar
  83. Sun, X., et al. 2006.Overexpression of von Hippel–Lindau tumor suppressor protein and antisense HIF-1alpha eradicates gliomas. Cancer Gene Ther, 13(4): 428–35.CrossRefPubMedGoogle Scholar
  84. Sunters, A., et al. 2003.FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem, 278(50): 49795–805.CrossRefPubMedGoogle Scholar
  85. Swinnen, J.V., Brusselmans, and K. Verhoeven, G. 2006.Increased lipogenesis in cancer cells: New players, novel targets. Curr Opin Clin Nutr Metab Care, 9(4): 358–65.CrossRefPubMedGoogle Scholar
  86. Tomita, K., et al. 2005.AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats. Alcohol Clin Exp Res, 29(12 Suppl): 240S–5S.PubMedGoogle Scholar
  87. Vander Heiden, M.G., et al. 2001.Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol, 21(17): 5899–912.CrossRefPubMedGoogle Scholar
  88. Vyssokikh, M.Y., et al. 2002.Bax releases cytochrome c preferentially from a complex between porin and adenine nucleotide translocator. Hexokinase activity suppresses this effect. Mol Biol Rep, 29(1–2): 93–6.CrossRefPubMedGoogle Scholar
  89. Warburg, O., 1930:Metabolism of Tumors. Arnold Constable, London.Google Scholar
  90. Watcharasit, P., et al. 2003.Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem, 278(49): 48872–9.CrossRefPubMedGoogle Scholar
  91. Weinhouse, S., 1972.Glycolysis, respiration, and anomalous gene expression in experimental hepatomas: G.H.A. Clowes memorial lecture. Cancer Res, 32(10): 2007–16.PubMedGoogle Scholar
  92. Williams, K.R., Reddigari, and S. Patel, G.L. 1985.Identification of a nucleic acid helix-destabilizing protein from rat liver as lactate dehydrogenase-5. Proc Natl Acad Sci USA, 82(16): 5260–4.CrossRefPubMedGoogle Scholar
  93. Wilson, J.E., 2003.Isozymes of mammalian hexokinase: Structure, subcellular localization and metabolic function. J Exp Biol, 206(Pt 12): 2049–57.CrossRefPubMedGoogle Scholar
  94. Wilson, J.E., 1995.Hexokinases. Rev Physiol Biochem Pharmacol, 126: 65–198.CrossRefPubMedGoogle Scholar
  95. Woods, A., et al. 2003.LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol, 13(22): 2004–8.CrossRefPubMedGoogle Scholar
  96. Wu, M., et al. 2007.Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol, 292(1): C125–C36.CrossRefPubMedGoogle Scholar
  97. Xie, G.C. and Wilson, J.E. 1988.Rat brain hexokinase: The hydrophobic N-terminus of the mitochondrially bound enzyme is inserted in the lipid bilayer. Arch Biochem Biophys, 267(2): 803–10.CrossRefPubMedGoogle Scholar
  98. Yu, J., et al. 2001.PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell, 7(3): 673–82.CrossRefPubMedGoogle Scholar
  99. Zhang, H., et al. 2007.HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell, 11(5): 407–20.CrossRefPubMedGoogle Scholar
  100. Zhu, W., et al. 2004.Regulation of FOXO3a by brain-derived neurotrophic factor in differentiated human SH-SY5Y neuroblastoma cells. Brain Res Mol Brain Res, 126(1): 45–56.CrossRefPubMedGoogle Scholar
  101. Zuurbier, C.J., Eerbeek, and O. Meijer, A.J. 2005.Ischemic preconditioning, insulin, and morphine all cause hexokinase redistribution. Am J Physiol Heart Circ Physiol, 289(1): H496–H9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  1. 1.J.G. Pastorino Department of Molecular Biology,University of Medicine and Dentistry of New Jersey, Stratford

Personalised recommendations